Your browser doesn't support javascript.
loading
The Asthma Impairment and Risk Questionnaire enhances the assessment of asthma control.
Chipps, Bradley; Zeiger, Robert S; Beuther, David A; Reibman, Joan; Wise, Robert A; McCann, William; Gilbert, Ileen; Eudicone, James M; Gandhi, Hitesh N; Harding, Gale; Cutts, Katelyn; George, Maureen; Murphy, Kevin R.
Afiliação
  • Chipps B; Capital Allergy and Respiratory Disease Center, Sacramento, California. Electronic address: bchipps@capitalallergy.com.
  • Zeiger RS; Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.
  • Beuther DA; Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado.
  • Reibman J; Department of Medicine, New York University (NYU) Grossman School of Medicine, New York, New York.
  • Wise RA; Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • McCann W; Allergy Partners, Asheville, North Carolina.
  • Gilbert I; BioPharmaceuticals Medical, AstraZeneca, Wilmington, Delaware.
  • Eudicone JM; BioPharmaceuticals Medical, AstraZeneca, Wilmington, Delaware.
  • Gandhi HN; BioPharmaceuticals Medical, AstraZeneca, Wilmington, Delaware.
  • Harding G; Patient-Centered Research, Evidera, Bethesda, Maryland.
  • Cutts K; Patient-Centered Research, Evidera, Bethesda, Maryland.
  • George M; Department of Nursing, Columbia University School of Nursing, New York, New York.
  • Murphy KR; Division of Allergy, Asthma and Immunology, Boys Town National Research Hospital, Boys Town, Nebraska.
Ann Allergy Asthma Immunol ; 131(4): 436-443.e1, 2023 10.
Article em En | MEDLINE | ID: mdl-37105501
BACKGROUND: Asthma control is often overestimated in routine practice, and despite advances in the understanding of immunopathology and the availability of new precision therapies, the burden of disease remains unacceptably high. OBJECTIVE: To compare the performance of the Asthma Impairment and Risk Questionnaire (AIRQ) with patient and physician assessments and the Asthma Control Test (ACT) in identifying asthma control. METHODS: Baseline data from a longitudinal study of the AIRQ were analyzed. Patients with asthma in the United States aged 12 years and older followed in 24 specialty practices and 1 specialty-affiliated primary care clinic were enrolled between May and November 2019. At entry, participants completed AIRQ and ACT, and participants and physicians completed 5-point Likert scale assessments of control. RESULTS: A total of 1112 participants were enrolled (mean [SD] age = 43.9 [19.3] years, 70% of the female sex, 78% White). Overall, 62% of participants rated themselves as well- or completely controlled, and 54% were rated comparably by physicians. The ACT classified 49% of participants as well-controlled, with 35% similarly categorized by AIRQ. Previous-year exacerbations were experienced by 32% of participants who self-rated as well- or completely controlled, 30% who were rated as well- or completely controlled by physicians, and 29% assessed as well-controlled by ACT, but only 15% of those classified as well-controlled by AIRQ. CONCLUSION: The burden of asthma is substantial in patients cared for by asthma specialists, and asthma control is overestimated by patients, physicians, and the symptom-based ACT. The AIRQ assesses risk in addition to symptom control and may serve to improve asthma control determination by assessing previous exacerbations.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Médicos / Asma Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Médicos / Asma Idioma: En Ano de publicação: 2023 Tipo de documento: Article